pivekimab sunirine
immunogen,milestone pharma
['cadenza', 'pivekimab', 'immunogen ', '$imgn']
immunogen presents updated findings from phase 2 cadenza trial of pivekimab sunirine in bpdcn patients at eha 2023 congress. $imgn #positive 
Real-time news analysis & sentiment scoring (+/-) for stocks
Powered by @streetbeat_com
From the creators of @uscongbuysnews
Disclosure: https://t.co/eNe8LEd7CU